(PHG) Koninklijke Philips N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PHG) Koninklijke Philips N.V. Complete Analysis Pack
Unlock Strategic Clarity
This Koninklijke Philips N.V. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and decision-making. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
MRI, CT and spectral CT
Philips' MRI, CT and spectral CT line sits in a hospital upgrade cycle that keeps demand for high-ticket imaging high. These are premium systems with recurring service revenue, so each installed base adds long-tail cash flow. The business also needs steady R&D and sales spend, which fits a Star in BCG terms.
Ultrasound systems
Ultrasound systems fit Star status: demand keeps rising in cardiology, general imaging, OB/GYN, and point-of-care care, and Philips pairs scanners with software, not just hardware. Philips reported 2025 sales of €18.0 billion, showing it has scale to fund this growing category. With a broad clinical footprint and an expanding market, ultrasound can still absorb investment while scaling.
Image-guided therapy
Image-guided therapy is a Star for Koninklijke Philips N.V. because it sits in a fast-growing, high-value market tied to minimally invasive care and hospital upgrades. In Philips 2025 results, the Image-Guided Therapy segment generated strong sales and keeps earning repeat revenue from installation, software, and lifecycle services, not just one-off equipment deals.
Acute patient monitoring
Acute patient monitoring fits the Star quadrant because connected ICU and ward monitoring stays central as hospitals move to digital, continuous care. Philips had 2024 sales of €18.0 billion, and this segment benefits from a large installed base that supports recurring upgrades and service revenue. Still, Philips must keep spending to defend share and refresh aging systems.
- Large installed base supports share
- Digital monitoring demand keeps rising
- Upgrade spend is still needed
Sleep and respiratory care
Sleep and respiratory care fits Stars because it serves a large chronic-care base that needs home use, repeat supplies, and ongoing clinical support. Philips still has strong brand reach in CPAP and ventilation, so this unit can keep scaling if demand stays firm, but it also carries heavy service and compliance costs after the recall shock. That mix makes it more of a growth asset than a cash cow.
- High-volume, repeat-use care
- Brand still supports share
- Support costs stay high
- Growth can offset spend
Philips’ Star Businesses: MRI, CT, Ultrasound, and More
Koninklijke Philips N.V.'s Stars are MRI, CT, spectral CT, ultrasound, image-guided therapy, and acute monitoring. In 2025, Philips reported €18.0 billion in sales, and these units gain from hospital upgrade cycles, recurring service income, and digital care demand. Sleep and respiratory care also has Star traits, but recall-related costs still weigh on it.
| Star area | Why it fits |
|---|---|
| MRI, CT, spectral CT | High-ticket upgrades, service revenue |
| Ultrasound | Broad clinical demand, software tie-ins |
| Image-guided therapy | Minimally invasive growth, repeat revenue |
| Acute monitoring | Connected ICU demand, upgrade cycle |
What is included in the product
Detailed Word Document
Philips BCG Matrix maps its businesses to guide invest, hold, or divest decisions.
Editable Excel File
One-page Philips BCG Matrix that quickly shows each business unit’s quadrant to reduce strategic planning guesswork
Reference Sources
Lists credible sources behind Koninklijke Philips N.V. assumptions, making the analysis easier to verify, trust, and use in decisions.
Cash Cows
Sonicare electric toothbrushes
Sonicare electric toothbrushes fit the Cash Cows box: a mature oral-care category with strong brand recall and steady demand. Replacement cycles are usually about 1–2 years, so sales repeat with limited new-market spend. That lets Koninklijke Philips N.V. keep cash generation high while investing less in growth than in newer segments.
Replacement brush heads
Replacement brush heads fit Philips’ cash-cow profile: they drive repeat buys and usually carry better margins than the handle itself. Philips reported 2024 group sales of about €18.0 billion, and its large Sonicare user base supports steady replenishment demand even in a mature oral-care market. That makes this a classic installed-base, recurring-revenue business.
Philips Avent infant feeding
Philips Avent infant feeding is a mature, globally sold line with steady demand from parents and retailers, so it fits the Cash Cow slot in Koninklijke Philips N.V.'s BCG mix. It grows slower than medical technology, but its trusted brand keeps volume stable and supports repeat sales with modest marketing and product spend. That makes it a good cash generator that can help fund higher-growth segments.
Norelco male grooming
Norelco male grooming sits in a mature shavers-and-trimmers market, so growth is slower than in Philips’ health-tech lines. Philips’ long brand equity and wide retail reach keep it a steady seller, which fits a Cash Cows role in the BCG Matrix.
In FY2025, Philips kept generating strong cash from Personal Health, and grooming benefits from repeat purchases and low need for heavy capex. That makes it more of a dependable cash engine than a high-growth bet.
- 成熟 market, low growth
- Strong Philips brand support
- Broad store and online reach
- Repeat buys drive cash flow
Installed-base service contracts
Installed-base service contracts are a classic cash cow for Koninklijke Philips N.V. because service, maintenance, and upgrades on imaging and patient-care systems keep revenue recurring after the initial sale. In 2024, Philips reported about €18.0 billion in sales, and this large hospital footprint helps support steady, high-repeat service income with stronger margins than new equipment sales.
- Recurring revenue from installed systems
- Large base in hospitals
- Low growth, high repeat demand
- Strong margin, cash-generating profile
Philips’ Cash Cows: Repeat Revenue From Trusted Brands
Sonicare, replacement brush heads, Avent, Norelco, and installed-base service contracts fit Cash Cows because they sit in mature markets, sell on repeat, and need limited growth spend. Philips reported about €18.0 billion in 2024 sales, and these lines help turn that installed base into steady cash in FY2025.
| Cash Cow driver | Why it fits |
|---|---|
| Sonicare and brush heads | Repeat buys, mature category |
| Avent and Norelco | Stable demand, strong brand |
| Installed-base service | Recurring, higher-margin revenue |
| Philips sales | About €18.0 billion in 2024 |
Full Version Awaits
Koninklijke Philips N.V. Reference Sources
You’re previewing the exact Koninklijke Philips N.V. BCG Matrix document you’ll receive after purchase. No demo content or placeholder pages—just the full, ready-to-use report. Once purchased, the same file is available for immediate download, printing, or presentation. It’s designed to give you clear strategic insight from the start.
Dogs
Teeth whitening kits
Teeth whitening kits are a crowded, low-differentiation niche, so this fits a Dog in Koninklijke Philips N.V.'s BCG Matrix. Growth is modest versus Philips' core HealthTech engine, which sits on a much larger multibillion-euro revenue base. This category is best managed for efficiency, cash discipline, and selective SKU pruning, not aggressive expansion.
Interdental cleaning aids
Interdental cleaning aids sit in a mature oral-care niche, and Philips does not seem to have the same scale edge here as in electric toothbrushes and brush heads. Low growth and weak pricing power point to a Dog in the BCG Matrix. In Philips’ 2025 portfolio mix, this kind of subcategory is unlikely to add much to profit growth.
Legacy EMR modules
Legacy EMR modules sit in Philips' Dogs bucket: healthcare software is crowded, and Philips' 2025 filings still do not show it as a standalone growth engine, unlike imaging and devices. With Epic and Oracle Health setting the pace, these older modules stay low-share and low-growth.
So they look like capital traps unless Philips can lift share or fold them into larger workflows. The one-line read: keep only the parts that support installed base and cash flow.
Low-end beauty devices
Low-end beauty devices sit in the Dogs bucket for Koninklijke Philips N.V. because the category is heavily commoditized, so pricing is weak and margins stay under pressure. Philips’ brand still carries more weight in core oral care than in lower-end beauty SKUs, and these lines are unlikely to deliver meaningful growth or market-share gains.
That makes them a capital-light hold at best, not a growth engine.
- High commoditization
- Weak pricing power
- Oral care is stronger
- Low growth upside
Manual oral-care lines
Manual brushes and basic oral-care items sit in Koninklijke Philips N.V.’s mature end of Oral Healthcare: low ticket size, limited differentiation, and no built-in upgrade cycle. Philips reported 2024 group sales of EUR 18.0 billion, with Personal Health under pressure, while connected Sonicare products support higher-margin repeat demand. So these manual lines look more like cash traps than growth assets.
- Low-margin, mature category
- No recurring upgrade cycle
- Weak fit for growth BCG view
Philips’ Dogs: Small, Slow, and Mostly Cash-Flow Cattle
Dogs in Koninklijke Philips N.V. are low-share, low-growth lines like manual oral-care and legacy software. Philips reported EUR 18.0 billion 2024 sales, but these niches lack the scale or pricing power to move profit. Keep them for cash, installed-base support, and only prune what drags returns.
| Dog segment | 2025/2024 cue | Read |
|---|---|---|
| Manual oral care | Low margin | Dog |
| Legacy EMR modules | Low share | Dog |
Question Marks
Digital pathology AI with Ibex
Philips’ digital pathology AI with Ibex fits a fast-growing market, with global digital pathology set to expand sharply as cancer volumes rise to 35 million cases by 2050, from 20 million in 2022. Philips is still a partner, not a leader, so it is building share through Ibex rather than owning the field. That makes it a Question Mark: attractive upside, but market position is still being formed.
NICO.LAB stroke AI collaboration
Stroke care is a big need: the World Stroke Organization says about 12.2 million people have a stroke each year, and fast triage can cut delays. Philips’ NICO.LAB collaboration uses AI-assisted workflow to enter this niche, but it is still a partnership-led, early-stage bet. That makes it a question mark: high potential, yet still unproven in scaled adoption.
Care management platforms
Care management platforms sit in Philips’ Question Marks: hospitals are digitizing pathways, so software-led care coordination is growing. Philips has a strong healthcare brand and broad installed base, but the field is crowded with Epic, Oracle Health, and Siemens Healthineers, so share is not easy to win. It needs focused investment now to turn demand into scale and lift its low-share position.
Enterprise diagnostic informatics
Enterprise diagnostic informatics should benefit as imaging volume and hospital digitization rise; over 96% of U.S. non-federal acute care hospitals already use certified EHRs, and imaging demand keeps pushing data workflows. Philips has products here, but software platforms scale slower than devices, so this looks like a classic invest-or-trim Question Mark.
- Growth tied to imaging and digitization
- Software is harder to scale
- Likely needs selective investment
Cloud-connected workflow software
Cloud-connected workflow software sits in a fast-growing connected-hospital market, and Philips can sell it with its devices and services. Still, standalone share is not yet proven, so the unit needs more spending and adoption before it can move from Question Mark to Star. Philips reported €18.0 billion in 2024 sales, which gives it scale to fund the push.
- Growing hospital cloud demand
- Bundle with Philips devices
- Standalone share still low
- Needs funding and adoption
Philips’ Software Bets Target Big Markets, But Share Remains Low
Philips’ Question Marks are software-led bets with clear demand but weak share: digital pathology AI, stroke workflow, care management, and cloud-connected informatics. They sit in growing markets, but adoption is still early, so Philips must keep funding to turn platform reach into scale.
| Area | Signal | Implication |
|---|---|---|
| Digital pathology AI | Cancer cases may reach 35m by 2050 | High growth, low share |
| Stroke AI | 12.2m strokes a year | Early-stage partnership |
| Care management | 96%+ U.S. hospitals use EHRs | Crowded, needs investment |
| Philips scale | €18.0bn sales in 2024 | Can fund the push |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.